Clene Inc. (CLNN)
| Market Cap | 47.80M -20.6% |
| Revenue (ttm) | 197,000 -31.1% |
| Net Income | -39.52M |
| EPS | -3.50 |
| Shares Out | 12.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 158,782 |
| Open | 3.670 |
| Previous Close | 3.620 |
| Day's Range | 3.480 - 3.840 |
| 52-Week Range | 3.480 - 13.500 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 32.20 (+765.59%) |
| Earnings Date | Aug 14, 2026 |
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinde... [Read more]
Financial Performance
In 2025, Clene's revenue was $200,000, a decrease of -41.52% compared to the previous year's $342,000. Losses were -$26.17 million, -33.57% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price target is $32.2, which is an increase of 765.59% from the latest price.
News
Clene Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A clinical-stage biotech is advancing an oral nanotherapeutic for ALS, showing consistent neurofilament reduction and survival benefits in trials. NDA submission is imminent, with a confirmatory phase III and targeted commercialization planned. Strong safety profile and pipeline potential in other neurodegenerative diseases were highlighted.
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C.
Clene Transcript: Emerging Growth Conference
Discussions with the FDA have focused on linking neurofilament reduction to clinical benefit in ALS, with consistent biomarker and functional improvements across multiple studies. A comprehensive NDA is set for submission in early Q4, aiming for a potential commercialization decision by summer 2027.
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19...
Clene reports Q2 EPS ($1.08), consensus (26c)
Reports Q2 revenue $90,000, consensus $48,800. “We plan to submit our new drug application for CNM-Au8 under the accelerated approval pathway for patients with ALS and believe the evidence connecting…
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-tre...
Clene Quarterly report: Q2 2026
Clene has published its Q2 2026 quarterly earnings report on August 14, 2026.
Clene Earnings release: Q2 2026
Clene released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Clene Transcript: Canaccord Genuity's 46th Annual Growth Conference
Recent agency meetings clarified that a 10% neurofilament light reduction, supported by robust concurrent control data, may support accelerated approval if linked to clinical benefit. NDA filing is targeted for early Q4, with a confirmatory phase III trial and additional financing planned.
Clene to Present at The Canaccord 46th Annual Growth Conference
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...
Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’
Roth Capital analyst Jonathan Aschoff reiterated a Buy rating and $30 price target on Clene (CLNN), noting that the company ended Q1 with $12.4M in pro forma cash, enough funding…
Clene reports Q1 EPS (69c), consensus (70c)
Reports Q1 revenue $15,000, consensus $33,830. “We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA and appreciate the Agency’s engagement as we advance…
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an ...
Clene Quarterly report: Q1 2026
Clene has published its Q1 2026 quarterly earnings report on May 14, 2026.
Clene Earnings release: Q1 2026
Clene released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Clene price target raised to $50 from $48 at Canaccord
Canaccord raised the firm’s price target on Clene (CLNN) to $50 from $48 and keeps a Buy rating on the shares. The firm noted the company recently announced that it…
Clene Transcript: Emerging Growth Conference 92
FDA feedback supports moving forward with an NDA based on neurofilament light reduction as a surrogate endpoint, with statistically significant results achieved in ALS studies. Additional funding has been secured, and a phase III MS trial is planned for next year.
Clene Announces $7 Million Underwritten Offering of Common Stock
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late cli...
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biophar...
Clene provides update on NDA for ALS following Type C meeting with FDA
Clene (CLNN) announced receipt of final meeting minutes following its recent Type C meeting with the FDA. During the meeting and confirmed in the final meeting minutes, the FDA stated…
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker d...
Clene Proxy statement: Proxy filing
Clene filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Clene Proxy statement: Proxy filing
Clene filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Clene reports FY25 EPS ($2.65), consensus ($2.35)
Reports FY25 revenue $200k, consensus $152k. “Our next key milestone is the upcoming Type C face-to-face meeting with the U.S. Food and Drug Administration on Clene’s (CLNN) biomarker and survival…
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 ...